Non-canonical peptides bound to MHC
MetadataShow full item record
Central to the initiation of a T cell dependent immune response is the recognition of major histocompatibility complex (MHC) class I or class II molecules (in humans termed HLA and in mice termed H-2) bound to antigenic peptide. T cell receptors (TCR) have programmed specificity for particular peptide/MHC complexes, which ensures focused immune responses are generated against the antigen source. To design effective peptide based vaccines a comprehensive understanding of the specific interactions between MHC molecules and peptide, and of TCR recognition of MHC/peptide is valuable. We place particular emphasis on non-canonical bound peptides and their use in immunotherapy studies. © 2009 Bentham Science Publishers Ltd.
Showing items related by title, author, creator and subject.
Namjoshi, Sarika M (2009)Recent developments in genetic engineering and biotechnology have resulted in anincrease in availability of therapeutic peptides and small anti-cytokines. Oraladministration is inappropriate as these molecules are unstable ...
Lazoura, E.; Lodding, J.; Farrugia, W.; Day, S.; Ramsland, Paul; Apostolopoulos, V. (2009)The major histocompatibility complex (MHC) on the surface of antigen presenting cells functions to display peptides to the T cell receptor (TCR). Recognition of peptide-MHC by T cells initiates a cascade of signals, which ...
Altered peptide ligands of myelin basic protein (MBP87-99) conjugated to reduced mannan modulate immune responses in miceKatsara, M.; Yuriev, E.; Ramsland, Paul; Tselios, T.; Deraos, G.; Lourbopoulos, A.; Grigoriadis, N.; Matsoukas, J.; Apostolopoulos, V. (2009)Mutations of peptides to generate altered peptide ligands, capable of switching immune responses from T helper 1 (Th1) to T helper 2 (Th2), are promising candidates for the immunotherapy of autoimmune diseases such as ...